ライフサイエンスコーパス: meningococcal

1 Pneumococcal (28/302 [9%]) and meningococcal (23/302 [8%]) meningitis were rare in the

2 A new meningococcal A conjugate vaccine (PsA-TT) is about to b

3 A safe, affordable, and highly immunogenic meningococcal A conjugate vaccine (PsA-TT, MenAfriVac) w

4 The monovalent meningococcal A conjugate vaccine (PsA-TT, MenAfriVac) w

5 cation (Africa and globally), development of meningococcal A disease vaccination campaigns in Africa,

6 In 2010, mass vaccination with a then-new meningococcal A polysaccharide-tetanus toxoid protein co

7 in LMICs, and the roll out of the MenAfriVac meningococcal A vaccine in the African Meningitis Belt r

8 those following a single dose of a licensed meningococcal ACWY polysaccharide vaccine (PsACWY).

9 Total meningococcal and genotypically serogroup B carriage pre

10 lution of the Neisseria, the epidemiology of meningococcal and gonococcal disease, and mechanisms of

11 nderstanding the variable pathophysiology of meningococcal and gonococcal infections given that after

12 itu hybridization (FISH) probes specific for meningococcal and gonococcal rRNA were used to demonstra

13 Meningococcal and HIV data abstracted from surveillance

14 ional validation datasets from patients with meningococcal and inflammatory diseases, bacterial infec

15 ren younger than 15 years with H influenzae, meningococcal and pneumococcal meningitis, and septicaem

16 nduces long-term sustained levels of group A meningococcal antibodies for up to 5 years after vaccina

17 The Meningococcal Antigen Typing System (MATS) was used to e

18 factor H-binding proteins representative of meningococcal B epidemiologic diversity; an hSBA titer o

19 cited bactericidal responses against diverse meningococcal B strains after doses 2 and 3 and was asso

20 We used 14 meningococcal B test strains that expressed vaccine-hete

21 effectiveness of the outer membrane vesicle meningococcal B vaccine (MeNZB) against gonorrhoea in yo

22 MenB-FHbp is a licensed meningococcal B vaccine targeting factor H-binding prote

23 survey, 20%-24% of participants carried any meningococcal bacteria and 4% carried serogroup B by rt-

24 13, CRM-conjugated) at 2-4 months and 1 or 2 meningococcal C vaccine (MCC-CRM- or MCC-TT) doses at 3-

25 Here 211 meningococcal carriage and >1,400 disease isolates were

26 MenB-4C do not have a large, rapid impact on meningococcal carriage and are unlikely to provide herd

27 easure the impact of vaccine introduction on meningococcal carriage and disease incidence.

28 cal (MenB) vaccines MenB-FHbp and MenB-4C on meningococcal carriage and herd protection.

29 ningococcal conjugate vaccine on serogroup Y meningococcal carriage and to define the dynamics of car

30 d 31% of the control group were positive for meningococcal carriage at study entry.

31 The inhibition of meningococcal carriage by N. lactamica is even more pote

32 e study; therefore, the impact of MCV4-DT on meningococcal carriage could not be determined.

33 We therefore assessed meningococcal carriage following a MenB vaccination camp

34 The prevalence of meningococcal carriage in the African meningitis belt is

35 nses and may be advantageous for maintaining meningococcal carriage in the nasopharynx.

36 Study of meningococcal carriage is essential to understanding the

37 he serogrouping and capsular genogrouping of meningococcal carriage isolates.

38 uitable approach for the characterization of meningococcal carriage isolates.

39 suggesting MenB-FHbp does not rapidly reduce meningococcal carriage or prevent serogroup B carriage a

40 in the 3 districts, overall postvaccination meningococcal carriage prevalence was 6.95%, with NmX do

41 vious study of Georgia high school students, meningococcal carriage prevalence was 7%.

42 rse, MenACWY-CRM and 4CMenB vaccines reduced meningococcal carriage rates during 12 months after vacc

43 -CRM) or serogroup B (4CMenB) vaccination on meningococcal carriage rates in 18-24-year-olds.

44 Meningococcal carriage rates in US high school students

45 In this group, meningococcal carriage reduced from 24.2% (36/149) at in

46 Among 3311 students, the prevalence of meningococcal carriage was 3.21%-4.01%.

47 Meningococcal carriage was evaluated in a subset (N = 53

48 Meningococcal carriage was highest in 24- to 39-year-old

49 The inhibition of meningococcal carriage was only observed in carriers of

50 Meningococcal carriage was studied in an age-stratified

51 Oropharyngeal swab cultures for meningococcal carriage were performed 3 times during the

52 xpression states during long-term persistent meningococcal carriage, in part due to continuous exposu

53 We investigated MenB-FHbp impact on meningococcal carriage.

54 CI, 1.1-1.5) were associated with increased meningococcal carriage.

55 n age and clinical manifestation and less on meningococcal CC or serogroup.

56 Meningococcal CCs were assessed by multilocus sequence t

57 nformation on the relation between infecting meningococcal clonal complex (CC), disease course and ou

58 cted after introduction of a new serogroup A meningococcal conjugate vaccine (MenAfriVac).

59 A group A meningococcal conjugate vaccine (PsA-TT) was developed s

60 ert consultations recommended that a group A meningococcal conjugate vaccine be developed and introdu

61 of HIV-infected persons with a quadrivalent meningococcal conjugate vaccine in accordance with Advis

62 of this study was to measure the impact of a meningococcal conjugate vaccine on serogroup Y meningoco

63 The regulatory pathway for this new group A meningococcal conjugate vaccine proved to be a useful tr

64 ccessfully scaled up production of a group A meningococcal conjugate vaccine that used SIIL tetanus t

65 participating schools received quadrivalent meningococcal conjugate vaccine that uses diphtheria tox

66 In a tetravalent A/C/Y/W-135-DT meningococcal conjugate vaccine vial, or in a final form

67 A new group A meningococcal conjugate vaccine was developed to elimina

68 The group A meningococcal conjugate vaccine was named MenAfriVac, an

69 The new group A meningococcal conjugate vaccine was well received, with

70 in the African meningitis belt with group A meningococcal conjugate vaccine, MenAfriVac (PsA-TT), di

71 that included the introduction of a group A meningococcal conjugate vaccine, PsA-TT (MenAfriVac), in

72 The recent introduction of a new group A meningococcal conjugate vaccine, PsA-TT (MenAfriVac), in

73 In 2012, a group A meningococcal conjugate vaccine, PsA-TT (MenAfriVac), wa

74 The group A meningococcal conjugate vaccine, PsA-TT, uses tetanus to

75 A group A meningococcal conjugate vaccine, PsA-TT, was licensed in

76 nd, to that end, worked to develop a group A meningococcal conjugate vaccine, PsA-TT.

77 Meningococcal conjugate vaccines against serogroups A, C

78 e World Health Organization (WHO) to develop meningococcal conjugate vaccines for sub-Saharan Africa.

79 Meningococcal conjugate vaccines protect individuals dir

80 recent publications on human papillomavirus, meningococcal conjugate, and tetanus and diphtheria toxo

81 following vaccines are reviewed: influenza, meningococcal conjugate, childhood and adolescent/adult

82 ation registry data and serogroup B invasive meningococcal disease (B-IMD) cases notified to public h

83 Invasive meningococcal disease (IMD) caused by Neisseria meningit

84 An association between HIV and invasive meningococcal disease (IMD) has been suggested by severa

85 Before 2001, the incidence of invasive meningococcal disease (IMD) in Canada was 1.0 per 100 00

86 Invasive meningococcal disease (IMD) incidence increased in Quebe

87 Invasive meningococcal disease (IMD) is a worldwide health issue

88 e information on clinical course of invasive meningococcal disease (IMD) is useful to evaluate cost-e

89 In contrast to invasive meningococcal disease (IMD) isolates, which can be readi

90 admitted to hospital with confirmed invasive meningococcal disease (IMD).

91 (TPD) are susceptible to recurrent invasive meningococcal disease (IMD).

92 Meningococcal disease (MD) remains an important infectio

93 ertaken in separate studies of children with meningococcal disease (n = 24) and inflammatory diseases

94 Several clusters of serogroup C meningococcal disease among men who have sex with men (M

95 The epidemiology and risk of meningococcal disease among MSM is not well described.

96 Annualized incidence of meningococcal disease among MSM was 0.56 cases per 10000

97 ective at prevention of serogroup A invasive meningococcal disease and carriage in Chad.

98 present a step forward in the battle against meningococcal disease and will help reassure that the va

99 Laboratory-confirmed cases of meningococcal disease are followed up with PHE local hea

100 ional pneumococcal serotypes and serogroup B meningococcal disease are important.

101 ary 2008 and November 2010, we identified 13 meningococcal disease cases (7 confirmed, 4 probable, an

102 All meningococcal disease cases among men aged 18-64 years r

103 Characteristics of meningococcal disease cases among MSM and men not known

104 Isolates from meningococcal disease cases among MSM were characterized

105 decrease, even as the proportion of invasive meningococcal disease cases caused by serogroup B has in

106 Serogroup B meningococcal disease caused 7 US university outbreaks d

107 gene family links to host susceptibility to meningococcal disease caused by infection with Neisseria

108 in 33.9% of vaccinees, although no cases of meningococcal disease caused by N. meningitidis B were r

109 nd to compare this protection to an invasive meningococcal disease challenge model.

110 Although serogroup C meningococcal disease has all but disappeared in the pas

111 England and Wales, the incidence of invasive meningococcal disease has been declining for more than a

112 aride vaccine developed to eliminate group A meningococcal disease in Africa.

113 s enhanced national surveillance of invasive meningococcal disease in England and Wales.

114 explanation for the large number of cases of meningococcal disease in immunized patients being treate

115 nation may provide better protection against meningococcal disease in patients treated with an AP-spe

116 lp explain the historically low incidence of meningococcal disease in the United States.

117 a spp. following the eighth case of invasive meningococcal disease in young children (5 to 46 months)

118 Meningococcal disease incidence in the United States is

119 Meningococcal disease increased during the 1990s, reachi

120 Group A meningococcal disease occurs in large epidemics within t

121 aign in response to a university serogroup B meningococcal disease outbreak in 2015.

122 Diagnosis of meningococcal disease relies on recognition of clinical

123 nd (PHE) undertakes enhanced surveillance of meningococcal disease through a combination of clinical,

124 r Sick Children (Belfast, UK) with suspected meningococcal disease were eligible for inclusion.

125 Seventy-four cases of meningococcal disease were reported among MSM and 453 am

126 MSM are at increased risk for meningococcal disease, although the incidence of disease

127 additional genes associated with serogroup Y meningococcal disease, and this work would benefit from

128 thogen responsible for outbreaks of invasive meningococcal disease, including among men who have sex

129 l pack of investigations and were tested for meningococcal disease, of whom 148 consented and were en

130 patients are at >1000-fold increased risk of meningococcal disease, vaccination is recommended; wheth

131 ization by commensal Neisseria lactamica and meningococcal disease, we investigated whether controlle

132 a major cause of severe sepsis and invasive meningococcal disease, which is associated with 5-15% mo

133 a multicomponent vaccine against serogroup B meningococcal disease-into the national infant immunisat

134 stain individual protection against invasive meningococcal disease.

135 cine licensed to protect against serogroup B meningococcal disease.

136 ogroup Y (MenY) strains are a major cause of meningococcal disease.

137 MenW was responsible for 15% of all invasive meningococcal disease.

138 arry tspB genes are associated with invasive meningococcal disease.

139 ngococcal pack of investigations testing for meningococcal disease.

140 tigen in vaccines being developed to prevent meningococcal disease.

141 in both CFH and CFHR3 and susceptibility to meningococcal disease.

142 n residential halls are at increased risk of meningococcal disease.

143 he most effective strategy for prevention of meningococcal disease.

144 e very infrequently associated with invasive meningococcal disease; however, those belonging to the '

145 and effective for the molecular detection of meningococcal DNA in clinical specimens.

146 cines have had minimal success in preventing meningococcal epidemics in the meningitis belt of Africa

147 ns have been licensed; both vaccines contain meningococcal factor H binding protein (fHbp).

148 Knocking out NspA, a known meningococcal FH ligand, converted both resistant isolat

149 p binds CFH with affinity similar to that of meningococcal fHbp and promotes survival of N. cinerea i

150 identified as being induced and repressed by meningococcal Fur.

151 meningitidis are possible across a range of meningococcal genotypes.

152 ration for the introduction of MenAfriVac, a meningococcal group A conjugate vaccine developed for th

153 A meningococcal group A conjugate vaccine, PsA-TT (MenAfri

154 oduction, the duration of protection against meningococcal group A is unknown.

155 Subjects received either PsA-TT; meningococcal group A, C, W, Y polysaccharide vaccine (P

156 d to estimate coverage by 4CMenB of invasive meningococcal group B isolates obtained during 2007-08 i

157 aimed to repeat the MATS survey for invasive meningococcal group B isolates obtained during 2014-15,

158 In 2014-15, 165 of 251 (66%; 95% CI 52-80) meningococcal group B isolates were estimated by MATS to

159 INTERPRETATION: In 2014-15, two-thirds of meningococcal group B isolates were predicted to be cove

160 nce data suggest that outer membrane vesicle meningococcal group B vaccines affect the incidence of g

161 s been declining for more than a decade, but meningococcal group W (MenW) cases have been increasing

162 No deaths or cases of meningococcal infection occurred during the study.

163 central nervous system (CNS) in response to meningococcal infection.

164 infection-related adverse events, including meningococcal infections, were observed through the exte

165 ve critical impact on the pathophysiology of meningococcal infections.

166 pective on regulatory mechanisms involved in meningococcal interaction with epithelial cells, and sug

167 e results suggested that GltT-GltM-dependent meningococcal internalization into HBMEC might be induce

168 We determined that nonencapsulated meningococcal isolates from an ongoing Nm urethritis out

169 Invasive serogroup B meningococcal isolates from cases in England, Wales, and

170 The population structure of US meningococcal isolates is dynamic; some changes occurred

171 Meningococcal isolates recovered during 2006-2010 (ie, a

172 tionality between galE1 and galE2 alleles in meningococcal isolates was retained for all serogroups e

173 knockout mutants prepared from two sensitive meningococcal isolates.

174 d from patients and tested with near-patient meningococcal LAMP and the results were compared with th

175 e aimed to assess the diagnostic accuracy of meningococcal LAMP as a near-patient test in the emergen

176 Meningococcal LAMP is straightforward enough for use in

177 At least 20 meningococcal lineages were identified, three of which (

178 ance induced by the more highly inflammatory meningococcal LOS was correlated with significantly grea

179 In 2010, Africa's first preventive meningococcal mass vaccination campaign was launched usi

180 ation aged 1-29 years with 1 dose of group A meningococcal (MenA) conjugate vaccine (PsA-TT, MenAfriV

181 elop, test, license, and introduce a group A meningococcal (MenA) conjugate vaccine for sub-Saharan A

182 A group A meningococcal (MenA) conjugate vaccine has progressively

183 A group A meningococcal (MenA) conjugate vaccine, PsA-TT (MenAfriV

184 e vaccines have been used to control group A meningococcal (MenA) epidemics with minimal success.

185 ntry to introduce the multicomponent group B meningococcal (MenB) vaccine (4CMenB, Bexsero) into a pu

186 bp (factor H binding protein), a serogroup B meningococcal (MenB) vaccine, was used to control a coll

187 data exist on the impact of the serogroup B meningococcal (MenB) vaccines MenB-FHbp and MenB-4C on m

188 asured before a booster of a Hib-serogroup C meningococcal (MenC) conjugate vaccine and again 1 week,

189 We studied the effect of PsA-TT on meningococcal meningitis and carriage in Chad during a s

190 o- or nasopharynx and the causative agent of meningococcal meningitis and meningococcemia, is capable

191 Subsequently the patient developed meningococcal meningitis and was admitted to the neuroin

192 Epidemics of meningococcal meningitis are concentrated in sub-Saharan

193 a pneumococcal seroprevalence study during a meningococcal meningitis epidemic in Western Burkina Fas

194 is and carriage in Chad during a serogroup A meningococcal meningitis epidemic.

195 After the major group A meningococcal meningitis epidemics in 1996-1997 (250,000

196 nsible for epidemics and almost all cases of meningococcal meningitis in the meningitis belt over the

197 eningitis at a time when the epidemiology of meningococcal meningitis on the continent is changing ra

198 These associations did not seem to apply to meningococcal meningitis or viral meningitis.

199 By contrast, meningococcal meningitis rates declined steadily, but re

200 a vaccine against the one cause of epidemic meningococcal meningitis that currently cannot be preven

201 nhanced surveillance, no case of serogroup A meningococcal meningitis was reported in the three vacci

202 tions, such as outbreaks of yellow fever and meningococcal meningitis.

203 nd a substantial effect on confirmed group A meningococcal meningitis.

204 cohort studies comprising 373 patients with meningococcal meningitis.

205 olates were surveyed for the distribution of meningococcal mod alleles.

206 Using meningococcal mutants that lacked all four of the above-

207 iagnosed between 20 and 55 years of age with meningococcal (n = 451), pneumococcal (n = 553), or vira

208 among persons who had a history of childhood meningococcal (n=1338), pneumococcal (n=455), and H. inf

209 s conferred by population-level reduction of meningococcal nasopharyngeal colonization.

210 and wild-type mice immunized with a control meningococcal native outer membrane vesicle vaccine had

211 The structural integrity of meningococcal native, micro-fluidized and activated caps

212 While a meningococcal NMB0419 mutant did not have altered epithe

213 ed or receiving disability pension in former meningococcal or viral meningitis patients versus member

214 ld be a novel bacterial medicine to suppress meningococcal outbreaks.

215 ren presenting at the hospital underwent the meningococcal pack of investigations and were tested for

216 Patients underwent a standard meningococcal pack of investigations testing for meningo

217 3% (90.6% vs 94.9%; 95% CI, 2.0%-6.6%) fewer meningococcal, pneumococcal, and H. influenzae meningiti

218 of Danish-born children diagnosed as having meningococcal, pneumococcal, or Haemophilus influenzae m

219 accepted technology transfer for the group A meningococcal polysaccharide from SynCo Bio Partners and

220 can be prevented by active immunization with meningococcal polysaccharide or polysaccharide-protein c

221 Although many years of application of meningococcal polysaccharide vaccines have had minimal s

222 A serogroup A meningococcal polysaccharide-tetanus toxoid conjugate va

223 mophilus influenzae type b (Hib) and group C meningococcal polysaccharides, as well as tetanus toxoid

224 reflect genetic diversity in the underlying meningococcal population rather than novel adaptation to

225 Information was also available on meningococcal population structure and vaccine (Bexsero,

226 The impact of these vaccines on the meningococcal population structure in the United States

227 e by whole-genome sequencing and compare the meningococcal population structure of Swedish invasive s

228 The meningococcal population structures were similar in the

229 We assessed the effects of meningococcal quadrivalent glycoconjugate (MenACWY-CRM)

230 rk would benefit from a complete serogroup Y meningococcal reference genome.

231 lipopolysaccharide, which are essential for meningococcal resistance against immune killing.

232 One patient had meningococcal sepsis and sterile meningitis about 2 mont

233 edia, pneumonia, bacteremia, meningitis, and meningococcal sepsis.

234 ing showed that inhibition affected multiple meningococcal sequence types.

235 the meningitis belt of sub-Saharan Africa, a meningococcal serogroup A conjugate vaccine (MACV) has b

236 In December 2013, a multicomponent meningococcal serogroup B (4CMenB) vaccine was used befo

237 blood from 12 healthy adults vaccinated with meningococcal serogroup B and serogroup A, C, W, Y vacci

238 accine approved in the USA for prevention of meningococcal serogroup B disease in 10-25-year-olds.

239 part of vaccines developed for prevention of meningococcal serogroup B disease.

240 ased vaccines, Bexsero and Trumenba, against meningococcal serogroup B strains have been licensed; bo

241 using human complement (hSBA) by use of four meningococcal serogroup B test strains expressing vaccin

242 e than 50% of participants for three of four meningococcal serogroup B test strains representative of

243 e than 50% of participants for three of four meningococcal serogroup B test strains representative of

244 The multicomponent meningococcal serogroup B vaccine (4CMenB) is an outer m

245 l countries consider the implementation of a meningococcal serogroup B vaccine for young children and

246 MenB-4C is a recently licensed meningococcal serogroup B vaccine.

247 o assess possible herd immunity effects with meningococcal serogroup B vaccines and the need for a bo

248 Vaccination with meningococcal serogroup C (MenC) conjugate (MCC) polysac

249 uring 2001-2005 all provinces introduced the meningococcal serogroup C conjugate vaccine (MCCV) into

250 milarities of meningococcal serogroup W with meningococcal serogroup C emergence, the rapid expansion

251 the PS-specific BMEM induced in humans by a meningococcal serogroup C PS (Men C)-TT conjugate vaccin

252 Hospital admissions decreased after the meningococcal serogroup C vaccine was introduced in 1999

253 tudy, we used national surveillance data for meningococcal serogroup W and serogroup C disease in the

254 Cases due to meningococcal serogroup W cc11 (MenW:cc11) emerged in 20

255 Since 2009, the incidence of meningococcal serogroup W disease has increased rapidly

256 In the Netherlands, the incidence of meningococcal serogroup W disease increased substantiall

257 ands has had an increase in the incidence of meningococcal serogroup W disease.

258 TATION: Given the historical similarities of meningococcal serogroup W with meningococcal serogroup C

259 olysaccharide vaccines are available against meningococcal serogroups A, C, W, and Y.

260 The meningococcal serogroups A, W, and X have been responsib

261 d remain vigilant against threats from other meningococcal serogroups and other pathogens.

262 ulted in significantly lower carriage of any meningococcal strain (18.2% [95% CI 3.4-30.8] carriage r

263 evel of lipid A phosphorylation, as LOS from meningococcal strain 89I with the highest degree of phos

264 amount of protein expressed by the different meningococcal strains and this could be predicted from t

265 Recently, meningococcal strains associated with outbreaks of ureth

266 nfant rats, which could inform the choice of meningococcal strains for use in animal models, and reve

267 ctericidal responses of the 2 groups against meningococcal strains susceptible to antibody to the Nad

268 mortality after lethal invasive doses of all meningococcal strains tested.

269 Unusual meningococcal strains with low level of virulence simila

270 thers have shown is associated with invasive meningococcal strains.

271 -related schedules for certain vaccines (eg, meningococcal; tetanus toxoid, reduced diphtheria toxoid

272 B, and exbD, based on a known phenotype of a meningococcal tonB mutant.

273 In conclusion, meningococcal TPS system 2 and/or 3 is associated with d

274 ium will allow for a better understanding of meningococcal transcriptome organization and riboregulat

275 y demonstrates how housing density can drive meningococcal transmission and carriage, which likely fa

276 ion documents, all participants had received meningococcal vaccination and the majority of those from

277 lue of a national recommendation for routine meningococcal vaccination of PLWHA.

278 s even more potent than after glycoconjugate meningococcal vaccination.

279 in SLSJ, using the 4-component protein-based meningococcal vaccine (MenB-4C).

280 d influenza vaccine (n=2108) or quadrivalent meningococcal vaccine (n=2085).

281 The group A meningococcal vaccine (PsA-TT) clinical development plan

282 During the first introduction of a group A meningococcal vaccine (PsA-TT) in 2010-2011 and its roll

283 The meningococcal vaccine antigen, factor H (FH)-binding pro

284 tibody production in mice and is a candidate meningococcal vaccine antigen.

285 embrane protein previously investigated as a meningococcal vaccine candidate.

286 cine group than in those in the quadrivalent meningococcal vaccine group (n=60 vs n=37; p=0.02).

287 eported in 60 (3%) women in the quadrivalent meningococcal vaccine group and 61 (3%) women in the tri

288 ere first episodes (n=77 in the quadrivalent meningococcal vaccine group vs n=52 in the trivalent ina

289 93 (88%) of 2041 infants in the quadrivalent meningococcal vaccine group were followed up until age 6

290 families and cost-effectiveness analyses for meningococcal vaccine programs.

291 was more common in women given quadrivalent meningococcal vaccine than in those given trivalent inac

292 i-TT), Vi-polysaccharide (Vi-PS), or control meningococcal vaccine with a computer-generated randomis

293 The rollout of the group A meningococcal vaccine, PsA-TT, in Africa's meningitis be

294 nactivated influenza vaccine or quadrivalent meningococcal vaccine.

295 Herd protection by meningococcal vaccines is conferred by population-level

296 Meningococcal vaccines that target both NspA and FHbp ar

297 ng protein (fHbp; a key component of group B meningococcal vaccines) molecule.

298 f tetanus/diphtheria/acellular pertussis and meningococcal vaccines, respectively, was delayed by 1 w

299 lopment not only for gonorrhoea but also for meningococcal vaccines.

300 how that capsular polysaccharide, a critical meningococcal virulence factor, inhibits the CP of compl

301 s known or hypothesized to have an impact on meningococcal virulence were shown to be associated with